Compare Rambus Inc. Common Stock (RMBS) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rambus Inc. Common Stock vs TransMedics Group Inc — how do they compare? Rambus Inc. Common Stock trades at $88.22 (market cap $9.99B), while TransMedics Group Inc trades at $75.02 (market cap $2.62B). The key difference: Rambus Inc. Common Stock is far larger — about 3.8× TransMedics Group Inc's market cap, and TransMedics Group Inc is more actively traded (891,435 versus 1,884,427). Which is the better fit depends on your goals — on Pluang, investors hold Rambus Inc. Common Stock for 0 Days and TransMedics Group Inc for 24 Days on average.
| RMBS | TMDX | |
|---|---|---|
Market Cap | $9.99B | $2.62B |
Volume | 1,884,427 | 891,435 |
Sector | Technology | Health |
52-Week High | $170.66 | $150.42 |
52-Week Low | $79.73 | $61.99 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $9.19B | $3.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rambus (RMBS) trades at $98.17, down 2.84% over 24 hours, with a neutral technical signal and key support at $96. The company reported strong profitability with a 31.69% net income margin and beat EPS estimates in two of the last three quarters. Recent news highlights its focus on AI infrastructure with new product launches, positioning it to benefit from growing demand for high-speed memory solutions.
The outlook is positive given analyst consensus of a $161.75 price target and 78.57% buy ratings, but risks include high valuation multiples and competitive pressures. Execution on AI-driven growth and maintaining earnings momentum are critical for stock appreciation, while any miss in upcoming results could pressure the premium valuation.
TransMedics Group (TMDX) trades at $79.135, up 1.23% on the day, but faces a bearish technical signal with recent earnings misses in Q1 and Q2 2026. The company maintains strong profitability with a 58.69% gross margin and 22.69% net margin, though net income is projected to decline in 2026. Recent news highlights insider buying and CFO appointment, but also ongoing legal investigations into fiduciary duties.
The stock presents a mixed outlook; analyst consensus is bullish with a $99.63 price target, but risks include margin pressure from heavy investment and legal overhangs. Upside hinges on execution against guidance, while downside is cushioned by solid cash flow and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Rambus Inc. Common Stock
Rambus Inc. is a semiconductor and silicon IP company that licenses chip interface and security technologies, including memory interface chipsets for DDR5 and DDR4 server and client DIMMs, interface IP for PCIe, CXL, and HBM, and security IP such as Root of Trust and memory encryption. It serves data center, AI, automotive, and IoT markets.
Read more on RMBS →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
